1. 1. Baloche V, Ferrand FR, Makowska A, Even C, Kontny U, Busson P (2020) Emerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges. Expert Opin Ther Targets, 24(6): 545-58. [DOI:10.1080/14728222.2020.1751820]

2. You R, Liu YP, Huang PY, Zou X, Sun R, He YX, et al. (2020) Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial. JAMA Oncol, 6(9): 1345-52. [DOI:10.1001/jamaoncol.2020.1808]

3. Ng WT, Soong YL, Ahn YC, AlHussain H, Choi HCW, Corry J, et al. (2021) International recommendations on reirradiation by intensity modulated radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys, 110(3): 682-95. [DOI:10.1016/j.ijrobp.2021.01.041]

4. Tang LL, Chen YP, Chen CB, Chen MY, Chen NY, Chen XZ, et al. (2021) The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun, 41(11): 1195-227. [DOI:10.1002/cac2.12218]

5. Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, et al. (2021) Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial. Nat Med, 27(9): 1536-43. [DOI:10.1038/s41591-021-01444-0]

6. Jiromaru R, Nakagawa T, Yasumatsu R (2022) Advanced nasopharyngeal carcinoma: current and emerging treatment options. Cancer Manag Res, 14: 2681-9. [DOI:10.2147/CMAR.S341472]

7. Zheng L, Tong L, Du F, Ren H, Xiao L (2021) Effect of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy on parotid gland function and quality of life in patients with nasopharyngeal carcinoma. Am J Transl Res, 13(5): 5272-9.

8. Gupta T, Sinha S, Ghosh-Laskar S, Budrukkar A, Mummudi N, Swain M, et al. (2020) Intensity-modulated radiation therapy versus three-dimensional conformal radiotherapy in head and neck squamous cell carcinoma: long-term and mature outcomes of a prospective randomized trial. Radiat Oncol, 15(1): 218. [DOI:10.1186/s13014-020-01666-5]

9. Fang Y, Wang L, Chen X, Cao C (2024) Maxillary sinus anterior wall recurrence after intensity-modulated radiotherapy for nasopharyngeal carcinoma. International Journal of Radiation Research, 22(1): 239-42. [DOI:10.61186/ijrr.22.3.803]

10. Ramadan LM and Abdelrazzak AB (2024) The non-targeted effect increases the risk of the radiation-induced myocardial injury. International Journal of Radiation Research, 22(2): 289-95. [DOI:10.61186/ijrr.22.2.289]

11. Liu Z, Chen Y, Su Y, Hu X, Peng X (2021) Nasopharyngeal carcinoma: Clinical achievements and considerations among treatment options. Front Oncol, 11: 635737. [DOI:10.3389/fonc.2021.635737]

12. Hommadi M, N'da G, Bertrand C, Randriamaroson N, Benlemlih M, Mosse WBA, et al. (2022) Volumetric modulated arctherapy for locally advanced nasopharyngeal carcinoma: Clinical efficacy and late toxicity. Cancer Radiother, 26(3): 433-9. [DOI:10.1016/j.canrad.2021.05.006]

13. Wu P, Zhao Y, Xiang L, Yang L (2020) Management of Chemotherapy for Stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A review. Cancer Manag Res, 12: 957-63. [DOI:10.2147/CMAR.S239729]

14. Killock D (2023) Recurrent nasopharyngeal carcinoma: hyperfractionation of IMRT improves outcomes. Nat Rev Clin Oncol, 20(5): 283. [DOI:10.1038/s41571-023-00753-2]

15. Tang LL, Guo R, Zhang N, Deng B, Chen L, Cheng ZB, et al. (2022) Effect of radiotherapy alone vs radiotherapy with concurrent chemoradiotherapy on survival without disease relapse in patients with low-risk nasopharyngeal carcinoma: a randomized clinical trial. JAMA, 328(8): 728-36. [DOI:10.1001/jama.2022.13997]

16. Lu S, Fan H, Hu X, Li X, Kuang Y, Yu D, et al. (2021) Dosimetric Comparison of helical tomotherapy, volume-modulated Arc therapy, and fixed-field intensity-modulated radiation therapy in locally advanced nasopharyngeal carcinoma. Front Oncol, 11: 764946. [DOI:10.3389/fonc.2021.764946]

17. Cantu G (2023) Nasopharyngeal carcinoma. A "different" head and neck tumour. Part B: treatment, prognostic factors, and outcomes. Acta Otorhinolaryngol Ital, 43(3): 155-69. [DOI:10.14639/0392-100X-N2223]

18. Zhan Y, Fan S. Multiple Mechanisms Involving in Radioresistance of Nasopharyngeal Carcinoma. J Cancer. 2020;11(14):4193-204. [DOI:10.7150/jca.39354]

19. Yao Z, Zhang B, Huang J, Shi L, Cheng B (2021) Publisher Correction: Radiation-induced acute injury of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy in induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a prospective cohort study. Sci Rep, 11(1): 17942. [DOI:10.1038/s41598-021-97814-2]

20. Liu YM, Peng YL, Li QW, Shen G, Ma YR, Chen MN, et al. (2021) Computed tomography-based evaluation of volume and position changes of the target region and organs at risk during radiotherapy for esophageal cancer: A pilot study. Front Oncol, 11: 702400. [DOI:10.3389/fonc.2021.702400]

21. Meng L, Teng F, Liu Q, Du L, Cai B, Xie C, et al. (2022) Long-term outcomes of nasopharyngeal carcinoma treated with helical tomotherapy using simultaneous integrated boost technique: A 10-year result. Front Oncol, 12: 1083440. [DOI:10.3389/fonc.2022.1083440]

22. Fan WJ, Teng F, Liu G, Zhao DW, Li JF, Luo YR, et al. (2021) Diffusion weighted imaging in submandibular gland sparing helical tomotherapy for nasopharyngeal carcinoma. Radiother Oncol, 157: 247-54. [DOI:10.1016/j.radonc.2021.02.004]

23. Lv X, Cao X, Xia WX, Liu KY, Qiang MY, Guo L, et al. (2021) Induction chemotherapy with lobaplatin and fluorouracil versus cisplatin and fluorouracil followed by chemoradiotherapy in patients with stage III-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised, controlled, phase 3 trial. Lancet Oncol, 22(5): 716-26. [DOI:10.1016/S1470-2045(21)00075-9]

24. Hua Y, You R, Wang Z, Huang P, Lin M, Ouyang Y, et al. (2021) Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial. J Immunother Cancer, 9(11): e003290. [DOI:10.1136/jitc-2021-003290]

25. Liu YP, Wen YH, Tang J, Wei Y, You R, Zhu XL, et al. (2021) Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol, 22(3): 381-90. [DOI:10.1016/S1470-2045(20)30673-2]

26. Lam JC, Wu VW, Chiu G, Kong PS, Wong CM (2020) A comparison of dose and set-up accuracy between flexed and extended neck positions in Helical Tomotherapy of nasopharyngeal carcinoma. Med Dosim, 45(3): 235-40. [DOI:10.1016/j.meddos.2019.12.005]

27. Zhao DW, Fan WJ, Fang XM, Luo YR, Wei J, Chen NX, et al. (2022) Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging. Radiother Oncol, 172: 91-8. [DOI:10.1016/j.radonc.2022.05.011]

28. Zhang J, Peng Y, Ding S, Zhu J, Liu Y, Chen M, et al. (2020) Comparison of different combinations of irradiation mode and jaw width in helical tomotherapy for nasopharyngeal carcinoma. Front Oncol, 10: 598. [DOI:10.3389/fonc.2020.00598]

29. Arslan SA (2020) Clinical outcomes of nasopharyngeal carcinoma patients treated with adaptive helical tomotherapy, A 5-year experience. Niger J Clin Pract, 23(12): 1683-9. [DOI:10.4103/njcp.njcp_647_19]

30. Luo Y, Cai B, Li B, Liu F, Du L, Zhao D, et al. (2022) The acute toxicities and efficacy of concurrent chemotherapy with docetaxel plus cisplatin, or docetaxel, or cisplatin and helical tomotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a randomized single-center phase II trial. Technol Cancer Res Treat, 21: 15330338221109974. [DOI:10.1177/15330338221109974]

31. You R, Liu YP, Xie YL, Lin C, Duan CY, Chen DP, et al. (2023) Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet, 401(10380): 917-27. [DOI:10.1016/S0140-6736(23)00269-6]